Keryx commences phase-3 trial for Zerenex

NEW YORK Keryx has begun its phase-3 clinicial trial of a drug designed to treat elevated serum phosphorous levels in patients with end-stage renal disease on dialysis.

The drug maker said that the Zerenex trial will include two clinical studies, examining approximately 300 ESRD patients on hemodialysis or peritoneal dialysis over a 52-week safety assessment period for a long-term efficacy study -- as well as 150 ESRD patients on hemodialysis or peritoneal dialysis over a 52-week safety assessment period for a short-term efficacy study -- to determine whether the investigational drug will treat elevated serum phosphorous levels, also known as hyperphosphatemia.

Patient enrollment is expected to take approximately six to nine months.

Login or Register to post a comment.